These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

406 related items for PubMed ID: 29294175

  • 1. Abatacept might increase bone mineral density at femoral neck for patients with rheumatoid arthritis in clinical practice: AIRTIGHT study.
    Tada M, Inui K, Sugioka Y, Mamoto K, Okano T, Koike T.
    Rheumatol Int; 2018 May; 38(5):777-784. PubMed ID: 29294175
    [Abstract] [Full Text] [Related]

  • 2. Association between Bone Mineral Density of Femoral Neck and Geriatric Nutritional Risk Index in Rheumatoid Arthritis Patients Treated with Biological Disease-Modifying Anti-Rheumatic Drugs.
    Tokumoto H, Tominaga H, Arishima Y, Jokoji G, Akimoto M, Ohtsubo H, Taketomi E, Sunahara N, Nagano S, Ishidou Y, Komiya S, Setoguchi T.
    Nutrients; 2018 Feb 18; 10(2):. PubMed ID: 29463015
    [Abstract] [Full Text] [Related]

  • 3. Effects of low dose methotrexate on the bone mineral density of patients with rheumatoid arthritis.
    Buckley LM, Leib ES, Cartularo KS, Vacek PM, Cooper SM.
    J Rheumatol; 1997 Aug 18; 24(8):1489-94. PubMed ID: 9263140
    [Abstract] [Full Text] [Related]

  • 4. Changes in bone density and bone turnover in patients with rheumatoid arthritis treated with rituximab, results from an exploratory, prospective study.
    Wheater G, Elshahaly M, Naraghi K, Tuck SP, Datta HK, van Laar JM.
    PLoS One; 2018 Aug 18; 13(8):e0201527. PubMed ID: 30080871
    [Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9. Tocilizumab potentially prevents bone loss in patients with anticitrullinated protein antibody-positive rheumatoid arthritis.
    Chen YM, Chen HH, Huang WN, Liao TL, Chen JP, Chao WC, Lin CT, Hung WT, Hsieh CW, Hsieh TY, Chen YH, Chen DY.
    PLoS One; 2017 Aug 18; 12(11):e0188454. PubMed ID: 29155868
    [Abstract] [Full Text] [Related]

  • 10. Different Effects of Biologics on Systemic Bone Loss Protection in Rheumatoid Arthritis: An Interim Analysis of a Three-Year Longitudinal Cohort Study.
    Chen MH, Yu SF, Chen JF, Chen WS, Liou TL, Chou CT, Hsu CY, Lai HM, Chen YC, Tsai CY, Cheng TT.
    Front Immunol; 2021 Aug 18; 12():783030. PubMed ID: 34987510
    [Abstract] [Full Text] [Related]

  • 11. Positive effect of alendronate on bone mineral density and markers of bone turnover in patients with rheumatoid arthritis on chronic treatment with low-dose prednisone: a randomized, double-blind, placebo-controlled trial.
    Lems WF, Lodder MC, Lips P, Bijlsma JW, Geusens P, Schrameijer N, van de Ven CM, Dijkmans BA.
    Osteoporos Int; 2006 Aug 18; 17(5):716-23. PubMed ID: 16463007
    [Abstract] [Full Text] [Related]

  • 12. Bone mineral density in rheumatoid arthritis patients 1 year after adalimumab therapy: arrest of bone loss.
    Wijbrandts CA, Klaasen R, Dijkgraaf MG, Gerlag DM, van Eck-Smit BL, Tak PP.
    Ann Rheum Dis; 2009 Mar 18; 68(3):373-6. PubMed ID: 18408246
    [Abstract] [Full Text] [Related]

  • 13. Long-term effects of infliximab on bone and cartilage turnover markers in patients with rheumatoid arthritis.
    Chopin F, Garnero P, le Henanff A, Debiais F, Daragon A, Roux C, Sany J, Wendling D, Zarnitsky C, Ravaud P, Thomas T.
    Ann Rheum Dis; 2008 Mar 18; 67(3):353-7. PubMed ID: 17644538
    [Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15. Comparison of the effect of 18-month daily teriparatide administration on patients with rheumatoid arthritis and postmenopausal osteoporosis patients.
    Ebina K, Hashimoto J, Shi K, Kashii M, Hirao M, Yoshikawa H.
    Osteoporos Int; 2014 Dec 18; 25(12):2755-65. PubMed ID: 25082556
    [Abstract] [Full Text] [Related]

  • 16. Risk factors for bone loss in patients with rheumatoid arthritis treated with biologic disease-modifying anti-rheumatic drugs.
    Tawaratsumida H, Setoguchi T, Arishima Y, Ohtsubo H, Akimoto M, Ishidou Y, Nagano S, Taketomi E, Sunahara N, Komiya S.
    BMC Res Notes; 2017 Dec 21; 10(1):765. PubMed ID: 29268799
    [Abstract] [Full Text] [Related]

  • 17. Decreased serum bone specific alkaline phosphatase and increased urinary N-terminal telopeptide of type I collagen as prognostic markers for bone mineral density loss in HIV patients on cART.
    Koga I, Seo K, Yoshino Y, Kitazawa T, Kurahashi I, Ota Y.
    J Infect Chemother; 2016 Aug 21; 22(8):543-7. PubMed ID: 27346381
    [Abstract] [Full Text] [Related]

  • 18. Is bone turnover a determinant of bone mass in rheumatoid arthritis?
    Cortet B, Flipo RM, Pigny P, Duquesnoy B, Boersma A, Marchandise X, Delcambre B.
    J Rheumatol; 1998 Dec 21; 25(12):2339-44. PubMed ID: 9858427
    [Abstract] [Full Text] [Related]

  • 19. Periarticular bone gain at proximal interphalangeal joints and changes in bone turnover markers in response to tumor necrosis factor inhibitors in rheumatoid and psoriatic arthritis.
    Szentpetery A, McKenna MJ, Murray BF, Ng CT, Brady JJ, Morrin M, Radovits B, Veale DJ, Fitzgerald O.
    J Rheumatol; 2013 May 21; 40(5):653-62. PubMed ID: 23457381
    [Abstract] [Full Text] [Related]

  • 20. Anti-tumor Necrosis Factor Therapy Increased Spine and Femoral Neck Bone Mineral Density of Patients with Active Ankylosing Spondylitis with Low Bone Mineral Density.
    Li H, Li Q, Chen X, Ji C, Gu J.
    J Rheumatol; 2015 Aug 21; 42(8):1413-7. PubMed ID: 26077412
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 21.